Santen Pharmaceutical Co Ltd (JP:4536)
:4536
Want to see JP:4536 full AI Analyst Report?
4536 Stock Chart & Stats
¥1597.00
-¥11.50(-0.71%)
At close: 4:00 PM EST
¥1597.00
-¥11.50(-0.71%)
Day’s Range― - ―
52-Week Range¥1,458.00 - ¥1,959.50
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.30M
Market Cap
¥612.35B
Enterprise Value¥536.27B
Total Cash (Recent Filing)¥80.88B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)15.7
Beta0.45
Next Earnings
Aug 06, 2026EPS Estimate
20.51Next Dividend Ex-DateN/A
Dividend Yield2.3%
Share Statistics
EPS (TTM)114.03
Shares Outstanding322,290,160
10 Day Avg. Volume1,416,570
30 Day Avg. Volume1,302,203
Financial Highlights & Ratios
PEG Ratio1.62
Price to Book (P/B)1.97
Price to Sales (P/S)2.01
P/FCF Ratio15.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)112.79
Revenue Forecast (FY)¥295.72B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetZero reported debt in 2026 and a sizable equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports sustained R&D and commercialization investment, and gives capacity for opportunistic M&A or shareholder returns during cyclical stress.
High Gross And Net MarginsSustained mid-50s gross margin and double-digit net margin indicate strong product economics typical of specialty pharma. Healthy margins support reinvestment into clinical development and commercialization, enabling durable profitability even if top-line growth is modest.
Focused Ophthalmology FranchiseA focused ophthalmology business model creates durable competitive advantages: specialized R&D, regulatory know-how, and established commercial channels. Niche focus and international presence support recurring prescription demand and pricing power versus generalist peers.
Bears Say
Earnings VolatilityHistorical swings including a 2023 net loss show earnings can be inconsistent, complicating long-range planning. Volatility undermines predictability of free cash flow and returns on equity, making it harder to reliably fund R&D, dividends, or large strategic initiatives.
Weaker Recent Cash ConversionA drop to ~0.5x operating cash flow coverage signals weaker conversion of accounting profits into cash. That reduces the company's internal funding capacity for development and commercial activities, increasing reliance on reserves or external funding in adverse periods.
Stagnant/slightly Negative Revenue TrendNegative multi-year revenue growth indicates limited top-line momentum and potential product maturity or competitive pressure. Without sustained new product launches or market share gains, stagnant revenue constrains long-term EPS and limits the benefits of high margins.
Santen Pharmaceutical Co News
4536 FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was ¥1458.00 and its highest was ¥1959.50 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is ¥612.35B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 76 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on May 12, 2026. The company reported ¥47.88 earnings per share for the quarter, beating the consensus estimate of ¥30.79 by ¥17.09.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of ¥19 which represents an annual dividend yield of 2.3%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate is 20.51.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,290,160 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of ¥47.88 in its last earnings report, beating expectations of ¥30.79. Following the earnings report the stock price went down -3.73%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4536
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. (Ticker: 4536) is a global pharmaceutical company headquartered in Japan, specializing in the research, development, manufacturing, and marketing of products primarily for ophthalmology. Established in 1890, Santen focuses on innovative treatments for various eye diseases and conditions, including glaucoma, retinal disorders, and dry eye disease. The company operates in multiple sectors, including prescription pharmaceuticals, over-the-counter (OTC) products, and medical devices, aiming to improve the quality of life for patients worldwide.
Technical Analysis
Astellas Pharma
―
Menicon Co
―
Nipro
―
Tsubota Laboratory Incorporated
―
Japan Eyewear Holdings Co.,Ltd.
―
Options Prices
Currently, No data available
---